Athersys (ATHX) Announces 1:25 Reverse Stock Split
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- S&P 500 inches lower as Middle East tensions outweigh tech gains
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
Athersys Announces 1-for-25 Reverse Stock Split
August 25, 2022 4:30 PM EDTCLEVELAND--(BUSINESS WIRE)-- Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today that it will be executing a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-25 after the close of trading on the Nasdaq Stock Market on Friday, August 26, 2022. Athersys common stock will begin trading on a split-adjusted basis when the market opens on Monday, August 29, 2022 under the existing trading symbol ATHX and a new CUSIP number. The reverse stock split was previously approved by Athersys stockholders at the... More
